Deka Bank Deutsche Girozentrale Savara Inc Transaction History

Deka Bank Deutsche Girozentrale

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$2.16 - $3.2 $44,496 - $65,920	-20,600 Closed	0 $0
Q2 2019 Aug 01, 2019	BUY	$2.37 - $11.7 $19,671 - $97,110	8,300 Added 67.48%	20,600 $50,000
Q1 2019 May 10, 2019	BUY	$6.71 - $8.6 $13,420 - $17,200	2,000 Added 19.42%	12,300 $141,000
Q4 2018 Feb 12, 2019	SELL	$6.27 - $10.92 $12,540 - $21,840	-2,000 Reduced 16.26%	10,300 $81,000
Q1 2018 May 03, 2018	BUY	$8.99 - $14.95 $110,577 - $183,885	12,300 New	12,300 $111,000

129

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $357M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.